Real-World Comparative Analysis of Polatuzumab Vedotin-Based Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone versus Standard Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Diffuse Large B-Cell Lymphoma: A Propensity Score-Matched Cohort Study

作者：Ziqian Wang, Chong Wei, Kaini Shen, Huacong Cai, Danqing Zhao, Daobin Zhou, Wei Zhang · 发表于：Oncology · 年份：2025 · DOI：10.1159/000549477 · 被引用次数：1 · 研究领域：Lymphoma Diagnosis and Treatment、Cutaneous lymphoproliferative disorders research、HER2/EGFR in Cancer Research

INTRODUCTION: The regimen of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) remains the standard first-line treatment for diffuse large B-cell lymphoma (DLBCL), yet many patients relapse. Polatuzumab vedotin combined with rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) has shown promise in trials. This study investigates the real-world efficacy and safety of Pola-R-CHP versus R-CHOP. METHODS: We retrospectively analyzed 505 DLBCL patients treated at Peking Union Medical College Hospital between January 2011 and March 2025. Thirty-six patients received Pola-R-CHP; 36 matched R-CHOP patients were selected using 1:1 propensity score matching based on age, sex, subtype, stage, and IPI. Outcomes included interim and end-of-treatment response, overall survival (OS), progression-free survival (PFS), and adverse events (AEs). RESULTS: Post-matching, 72 patients were included. Pola-R-CHP achieved higher interim complete response (CR) (72.2% vs. 63.9%, p = 0.035) and objective response rate (ORR) (100.0% vs. 83.3%, p = 0.011). At the end of treatment, CR was further improved (88.9% vs. 63.9%, p = 0.007), and ORR remained superior (100.0% vs. 86.1%, p = 0.020). At a median follow-up of 13.3 months (range, 1.1-141.9 months), 1 death and 2 progressions occurred in the Pola-R-CHP group compared with 9 deaths and 9 progressions in the R-CHOP group. Median OS and PFS were not reached in either cohort. At 12 months, the estimated OS was 97...